Is CRESCENT BIOPHARMA, INC. (CBIO) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.4% / 30% | 58.0% / 30% | 4.9% / 30% | 26.51% / 5% | ✗ NOT HALAL |
| DJIM | 0.4% / 33% | 58.0% / 33% | 4.9% / 33% | 26.51% / 5% | ✗ NOT HALAL |
| MSCI | 0.7% / 33% | 88.7% / 33% | 7.5% / 33% | 26.51% / 5% | ✗ NOT HALAL |
| S&P | 0.4% / 33% | 58.0% / 33% | 4.9% / 33% | 26.51% / 5% | ✗ NOT HALAL |
| FTSE | 0.7% / 33% | 88.7% / 33% | 7.5% / 50% | 26.51% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 100.0% | |
| Operating Margin | -843.7% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -160.7% | |
| Return on Assets (ROA) | -69.1% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$72M |
| Free Cash Flow | -$144M |
| Total Debt | $2M |
| Debt-to-Equity | 0.8 |
| Current Ratio | 6.6 |
| Total Assets | $240M |
Price & Trading
| Last Close | $13.50 |
| 50-Day MA | $11.29 |
| 200-Day MA | $12.68 |
| Avg Volume | 175K |
|
52-Week Range
$8.72
| |
About CRESCENT BIOPHARMA, INC. (CBIO)
Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the development and commercialization of oncology therapeutics. The company was formerly known as GlycoMimetics, Inc. The company was founded in 2024 and is headquartered in Waltham, Massachusetts.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is CRESCENT BIOPHARMA, INC. (CBIO) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), CRESCENT BIOPHARMA, INC. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is CRESCENT BIOPHARMA, INC.'s debt ratio?
CRESCENT BIOPHARMA, INC.'s debt ratio is 0.4% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 0.7%.
What are CRESCENT BIOPHARMA, INC.'s key financial metrics?
CRESCENT BIOPHARMA, INC. has a market capitalization of $462M, and revenue of $11M. Return on equity stands at -160.7%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.